Anavex/AVXL

$3.89

-4.42%
-
1D1W1MYTD1YMAX

About Anavex

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease, and other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (MECP2). The Company’s product candidates include NAVEX 3-71, ANAVEX 1-41, and ANAVEX 1066. ANAVEX 3-71 is a central nervous system (CNS) penetrable potential disease modifying treatment for cognitive impairments. ANAVEX 1-41 is a sigma-1 agonist.

Ticker

AVXL

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Christopher Missling

Employees

40

Headquarters

New york, United States

Anavex Metrics

BasicAdvanced
$344M
Market cap
-
P/E ratio
-$0.50
EPS
0.67
Beta
-
Dividend rate
$344M
0.66922
$10.45
$3.25
1.2M
15.12
-26.73%
-28.98%
-28.98%
2.522
2.553
26.69%

What the Analysts think about Anavex

Analyst Ratings

Majority rating from 2 analysts.
Buy

Price Targets

Average projection from 2 analysts.
606.94% upside
High $40.00
Low $15.00
$3.89
Current price
$27.50
Average price target

Anavex Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q2 24
QoQ growth
Revenue
$0
NaN%
Net income
-$11M
22.09%
Profit margin
0%
NaN%

Anavex Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 18.18%
QuarterlyAnnual
Q3 23
Q4 23
Q1 24
Q2 24
Q3 24
Actual
-$0.14
-$0.12
-$0.11
-$0.13
-
Expected
-$0.17
-$0.15
-$0.15
-$0.11
-$0.14
Surprise
-16%
-18.18%
-24.14%
18.18%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Anavex stock?

Anavex (AVXL) has a market cap of $344M as of May 30, 2024.

What is the P/E ratio for Anavex stock?

The price to earnings (P/E) ratio for Anavex (AVXL) stock is 0 as of May 30, 2024.

Does Anavex stock pay dividends?

No, Anavex (AVXL) stock does not pay dividends to its shareholders as of May 30, 2024.

When is the next Anavex dividend payment date?

Anavex (AVXL) stock does not pay dividends to its shareholders.

What is the beta indicator for Anavex?

Anavex (AVXL) has a beta rating of 0.67. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Anavex stock price target?

The target price for Anavex (AVXL) stock is $27.5, which is 606.94% above the current price of $3.89. This is an average based on projections from 2 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Anavex stock

Buy or sell Anavex stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing